论文部分内容阅读
目的 探讨激素抵抗型和激素敏感型哮喘急性发作时 ,雾化吸入利多卡因的临床疗效。方法 采用随机、双盲、对照的方法 ,进行了前瞻性研究。哮喘急性发作患者 ,分为A、B两组 :A组 (18例 )为激素抵抗型哮喘 ;B组 (18例 )为激素敏感型。随机各自分为A1 、A2 和B1 、B2 组 ,每组 9例。在常规治疗的基础上 ,A2 和B1 组雾化吸入利多卡因 ,作为实验组 ;A1 和B2 组则雾化吸入生理盐水 ,作为对照组。结果 试验组与对照组在心率、呼吸频率、呼气流速峰值 (PEF)、第一秒用力呼气量 (FEV1 )等方面 ,差异有显著性意义 (P <0 0 5 )。A2 与B1 的各项监测指标 ,无明显差异 ;A1 与B2 的差异较大 ,但其数据的比较 ,均无统计学意义 (P >0 0 5 )。结论 哮喘急性发作时 ,加用利多卡因雾化吸入治疗 ,临床疗效良好 ,尤其是激素抵抗型哮喘。
Objective To investigate the clinical efficacy of inhaled lidocaine in the treatment of acute exacerbation of steroid-resistant and hormone-sensitive asthma. Methods A prospective study was conducted using a randomized, double-blind, controlled approach. Patients with acute asthma attack were divided into A and B groups: group A (18 cases) were hormone-resistant asthma; group B (18 cases) were hormone-sensitive. Randomly divided into A1, A2 and B1, B2 group, 9 cases in each group. On the basis of routine treatment, group A2 and B1 inhaled lidocaine atomized, as the experimental group; group A1 and B2 inhaled normal saline as a control group. Results The heart rate, respiratory rate, peak expiratory flow rate (PEF) and forced expiratory volume in the first second (FEV1) of the experimental group and the control group were significantly different (P <0.05). A2 and B1 of the monitoring indicators, no significant difference; A1 and B2 are quite different, but the data were not statistically significant (P> 0.05). Conclusions Acute asthma attack, plus lidocaine inhalation therapy, clinical efficacy, especially hormone-resistant asthma.